Open Gynecologic Cancer Clinical Trials

Gynecologic Cancer Studies Currently Recruiting Participants at Simmons CancerResearch Center at Southern Illinois University

Protocol Title	Study #	Study Group
The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study	CTSU-NCCTG N08CA	CICCOP
Phase II Randomized Trial of the Combination of ABT-888 With Metronomic Oral Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low Grade Non-Hodgkin’s Lymphoma	SCI 11-022	SCI

Cervical

A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) Versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, In Stage IVB, Recurrent or Persistent Carcinoma of the Cervix	GOG 0240	CICCOP
A Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy	CTSU/RTOG 0724	CICCOP

Ovarian

A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer	GOG 0262	CICCOP
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary	GOG 0264	CICCOP
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy	GOG 0212	CICCOP
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer	GOG 0213	CICCOP
Nurse-Delivered Write Symptoms vs Self-Directed Write Symptoms vs Care as usual for optimal symptom management for women with Recurrent Ovarian, Fallopian Tube or Primary Peritoneal cancer	GOG 0259	CICCOP
A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma NCISupplied Agent(s): Bevacizumab (NSC #704865, IND #7921)	GOG 0252	CICCOP

Uterine

Weekly Exercise Minutes and Psychosocial Benefits in Endometrial Cancer Survivers	MEND Endometrial Cancer Study	SIU IM
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma	GOG 0249	CICCOP
A Phase II Evaluation of AZD6244 (NSC# 748727, CTEP IND #77782) in Women with Recurrent or Persistent Endometrial Carcinoma	GOG 0229H	CICCOP
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus	GOG 0261	CICCOP
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma	GOG 0258	CICCOP
A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865, IND #7921) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus	GOG 0250	CICCOP
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer	RTOG 0921	RTOG

Vulvar

Cancer Care/Symptom Management

Alterations in Neuropsychological Functioning in Adults Receiving Chemotherapy for Systemic and/or Adjuvant Disease Treatment

09-140

SCI

Although our objective is to provide an updated listing of available clinical trials please note that a listing here does not guarantee that a trial is open or available to any specific patient and that there may be additional trials available that are not listed. Complete information is only available from a treating physician.

Contact Information:

Simmons Cancer Institute Clinical Trials Office
Mail Code 9677 Fax (217) 545-6823

Kathy Robinson, PhD,
Director of Clinical Trials
(217) 545-1946
: Allicent Curry, RN,BSN, OCN
Research Nurse
(217) 545-7929

SIU COG

Carol Peterson, RN, CCRP (217) 545-7377

SIU IM

Amanda Fogleman, B.S. (217) 545-0592

Krista Whitlock (217) 545-7750

SIU Thoracic

Theresa Boley, RN, MSN, APN/FNP-BC, CCRP (217) 545-5000
: Cathy Leslie, RN, CCRP (217) 545-8184; Mary Ray, MS (217) 545-7420

RTOG: Radiation Therapy Oncology Group:

Diana Weyhenmeyer, RN, MA, OCN (217) 544-6464 ext. 45591

CICCOP: Central Illinois Community Clinical Oncology Program
Memorial Medical Center CICCOP Research Contacts:

Treatment/Cancer Control:

Holly Thomas (217) 788-4178

Stephanie Allbritton (217) 788-3544

Brooke Trickey (217) 217-788-3560

Karen Graber (217) 588-2961

Chrissy Tucker (217) 788-4444
Sunny Hampsey (217) 788-4233

Back to Open Clinical Trials